T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

MLA

Alison J. Moskowitz, et al. “T099: High Efficacy and Durability of Second-Line Therapy with Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in the Phase II Study for Relapsed and Refractory Hodgkin Lymphoma.” HemaSphere, vol. 6, Oct. 2022, pp. 45–46. EBSCOhost, https://doi.org/10.1097/01.HS9.0000890964.54059.2c.

APA

Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, Samia Sohail, Alayna Santarosa, Charisse Capadona, Brittney Munayirji, Anita Kumar, Oscar Lahoud, Connie Batlevi, Paul Hamlin, David J. Straus, Colette Owens, Philip Caron, Andrew Intlekofer, … Craig H. Moskowitz. (2022). T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma. HemaSphere, 6, 45–46. https://doi.org/10.1097/01.HS9.0000890964.54059.2c

Chicago

Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, et al. 2022. “T099: High Efficacy and Durability of Second-Line Therapy with Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in the Phase II Study for Relapsed and Refractory Hodgkin Lymphoma.” HemaSphere 6 (October): 45–46. doi:10.1097/01.HS9.0000890964.54059.2c.